Conference item : Abstract
Efficacy and safety of baricitinib versus placebo and adalimumab in patients with moderately to severely active rheumatoid arthritis and inadequate response to methotrexate: Summary results from the 52-week phase 3 RA-beam study
- Publication status:
- Published
- Peer review status:
- Reviewed (other)
Actions
Access Document
- Files:
-
-
(Preview, Accepted manuscript, pdf, 137.5KB, Terms of use)
-
- Publisher copy:
- 10.1093/rheumatology/kex061.001
Authors
- Publisher:
- Oxford University Press
- Host title:
- Rheumatology
- Journal:
- Rheumatology More from this journal
- Volume:
- 56
- Issue:
- S2
- Pages:
- 26-27
- Publication date:
- 2017-04-21
- Acceptance date:
- 2017-01-15
- DOI:
- EISSN:
-
1462-0332
- ISSN:
-
1462-0324
- Subtype:
-
Abstract
- Pubs id:
-
pubs:858239
- UUID:
-
uuid:5ed802b5-99ff-4d3e-8090-3e6849a71477
- Local pid:
-
pubs:858239
- Source identifiers:
-
858239
- Deposit date:
-
2019-02-13
- ARK identifier:
Terms of use
- Copyright holder:
- Taylor et al
- Copyright date:
- 2017
- Notes:
- © The Author 2017. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. This is a conference paper presented at the British Society for Rheumatology annual meeting 2017. This is the accepted manuscript version of the article. The final version is available online from Oxford University Press at: https://doi.org/10.1093/rheumatology/kex061.001
If you are the owner of this record, you can report an update to it here: Report update to this record